U.S. markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.96+0.39 (+0.76%)
At close: 4:00PM EDT

51.96 -0.00 (-0.00%)
After hours: 4:35PM EDT

Sign in to post a message.
  • H
    Haluk
    BRASILIA (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca (NYSE:AZN) and Oxford University has died, stating it had received data from an investigation into the matter.

    The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said that the volunteer was Brazilian.
  • c
    cristian
    People need to Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.” Reuters!
  • G
    Green Machine
    I bet they announce resuming the US trial today. Or maybe tomorrow. When they do, that should give this a boost up a little bit. Good luck all!
  • B
    Birwa
    It’s a fake news guys. The volunteer in Brazil never received the vaccine.
    They have not even stopped the trial in Brazil.
    Do your DD before selling.
    Well, do whatever, more it drops, better for us longs to buy more.
    Bullish
  • G
    Green Machine
    Good time to buy! We are currently right at our 100 day support level, with an RSI of 37 signaling this is oversold. This would be a good time to buy, or buy some more to lower your cost basis per share. It should be up from here. Good luck to all!
  • S
    Skillzz
    Brazil says volunteer died during Oxford vaccine trial

    [10/21/20] 13:07:00

    Brazil's health authority, Anvisa, announced on Wednesday that a volunteer passed away after receiving the AstraZeneca/Oxford University COVID-19 vaccine in a trial.

    Meanwhile, the Brazil Federal University of Sao Paulo noted the individual that passed away was a Brazilian national.

    AstraZeneca shares were trading 2.24% lower at 11:05 am ET.
  • S
    Soopa
    DoD IMMEDIATE RELEASE

    Trump Administration Expands Collaboration With AstraZeneca to Develop and Manufacture an Investigational Monoclonal Antibody to Prevent COVID-19
    OCT. 14, 2020
    To meet the Trump Administration’s Operation Warp Speed goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) today announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company’s COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, that may help treat or prevent infection with SARS-CoV-2, the coronavirus that causes COVID-19.

    The goal of AstraZeneca’s partnership with the U.S. Government is to develop a monoclonal antibody cocktail that can help prevent infection. An effective monoclonal antibody that can prevent COVID-19, particularly one that is long-lasting and delivered by intramuscular injection, may be of particular use in certain groups. This includes people who have compromised immune function, those who are over 80 years old, and people undergoing medical treatments that preclude them from receiving a COVID-19 vaccine. If the FDA authorizes use of AZD7442 for prevention of SARS-CoV-2, as outlined in agency guidance, the federal government will distribute the doses at no cost. As is customary with government-purchased medical products, healthcare professionals could charge for the cost of administering the product.

    The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, collaborated with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command, to provide approximately $486 million to AstraZeneca for two Phase 3 clinical trials and related development activities, including a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States.

    One of the Phase 3 clinical trials of AZD7442 will evaluate safety and efficacy of the product to prevent infection for up to 12 months in approximately 5,000 volunteers. An additional Phase 3 clinical study will evaluate if AZD7442 can help prevent infection in people who have come in contact with someone with COVID-19 in a post-exposure prophylaxis setting. This second study will enroll approximately 1,100 volunteers. The company estimates 100,000 doses of AZD 7442 could be available from this project for the nation’s high-risk population that may not benefit from a vaccine by December 2020.

    “In addition to Operation Warp Speed’s historic progress on vaccines, we are supporting promising monoclonal antibodies for prevention and treatment all the way through to supply, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar. “More good news about COVID-19 treatments is constantly emerging, and President Trump’s commitment to supporting lifesaving measures, like AstraZeneca’s antibody candidate which may help deliver these products to our nation’s most vulnerable populations.”

    Working in parallel across clinical development and manufacturing supply will accelerate the traditional product development timeline, should clinical trials prove successful and the U.S. Food and Drug Administration (FDA) authorize use of the medicine.

    AZD7442 is a combination of two monoclonal antibodies discovered by Vanderbilt University, licensed to AstraZeneca and modified using AstraZeneca’s proprietary half-life extension technology to extend their duration of action (the amount of time that the antibodies remain in the body). Monoclonal antibodies synthesized in the laboratory aim to mimic natural antibodies and are delivered by injection or infusion. The antibodies bind to the SARS-CoV-2 virus spike protein, reducing the ability of the virus to infect human cells. The long-acting monoclonal antibody combination neutralizes the SARS-CoV-2, and has the potential to increase effectiveness and durability of the prevention of infection.

    Preclinical and clinical development for this antiviral has been supported in part through an existing partnership among BARDA, the Defense Advanced Research Projects Agency, Vanderbilt University and AstraZeneca
  • G
    Green Machine
    There are currently 2,151 open call contracts for the $56 strike price for Oct 30th. That's a good sign as to where this share price should be headed soon.
  • S
    Scott
    You buy the "dips" and hold for an easy Triple if AZN coronavirus is approved. And in a week or so AZN should restart trials in U.S. thus pushing it over $70 a share. MRNA is a one trick pony and JNJ and Eli Lilly have both been halted. Pfe and BnTx have to supper freeze their vaccine and no one is set up to handle that on a mass quantity. Heck there are not enough deep freezer to store Bntx vaccine, much less enough dry ice to ship it. In other words Pfizer can't distribute, even if has the goods.

    AZN stock is cheap right now but you need to buy before it pops over $65 a share this month, if not sooner.
  • S
    Steve
    Breaking News - Jerry will not only lose his house "shorting AZN" but also his 2003 dented Camry. Wife left several months ago due to his "short stock" gambling habit and now he's just weeks away from home foreclosure. Keep posting Jerry, since everyone knows you'll be gone by next week if not sooner.
  • G
    Green Machine
    I could see us getting to $55 by the end of this week, and maybe $60 by the end of next week at the rate this has been climbing every week. Good luck all!
  • G
    Green Machine
    This is a HUGE company, which is a slow but steady gainer over time. And, it also pays a good dividend while you wait for your gains. It doesn't move up super fast usually, but at the same time, it doesn't take large quick dips either. Plus, it has the potential to jump up a little bit once the results of the phase 2/3 vaccine trial are released. Good luck to all!
  • G
    George
    $VXRT conversation
    first volunteer for the astrozeneca vaccine has died. (i kid you not) $AZN, and yet they are only down .6%
  • G
    Green Machine
    This is an awesome buy in point now to get a good deal on some AstraZenca stock. We are below the 50 day moving average, and the RSI is at 21 signaling that this is Oversold. Good luck all!
  • S
    Shaw
    Inovio Pharmaceuticals, Inc.
    Adenovirus based approach seems quite risky, and incidents seen in $AZN and $JNJ vaccines can't be just random. I'm thinking to reduce my position in $VXRT, as their oral vaccine is built upon Adenovirus too.

    I feel more comfortable and confident in inovio's DNA platform.

    https://www.bloomberg.com/news/articles/2020-10-17/ailments-in-covid-19-trials-raise-questions-about-vaccine-method
    Ailments in Covid-19 Trials Raise Questions About Vaccine Method
    www.bloomberg.com
  • w
    win
    "Overall, AZN scores a Strong Buy consensus from the analyst community with 4 unanimous Buy ratings. Looking ahead, the $77.38 average analyst price target puts the upside potential at a promising 41% in the coming 12 months."
    Bullish
  • G
    Green Machine
    I think we'll erase this 1/2 percent loss and close in the green today. This is a good entry price right now. I don't think it will be too much longer before this goes on a several day run and gets up over $60 again. Good luck all!
  • G
    Green Machine
    $52 plus by close today. $53 - $54 by close tomorrow to end the week. Then next week in the $54 - $57 area is my guess. Raise all these guesses by about 2 dollars if they announce that the phase 2/3 U.S. trial is resumming which I believe will be coming here very soon. Good luck all! Except you Jerry....you're depressing.